JA OTS Limited Source Justification_ATLAS.pdf

Last Modified: May 18, 2016 Page 1 of 7

General Services Administration Federal Supply Schedule Limited Source Justification

1. Identification of the agency and contracting activity:

a. Federal agency and contracting activity.

Department of Health and Human Services/Food and Drug Administration (HHS/FDA)

b. Sponsoring organization.

Office of Operations (OO) / Office of Talent Solutions (OTS)

c. Contracting Officer’s Representative (COR)/Requiring Activity Point of Contact (POC) information.

i. Name: Maria Runge

ii. Mailing address: 3 White Flint North, Room 05A17, North Bethesda, MD 20852

iii. E-mail address: maria.runge@fda.hhs.gov

iv. Telephone number: (240) 402-6569

2. Nature and/or description of the action being approved.

Award of a non-competitive, single-award Blanket Purchase Agreement (BPA) against General Services Administration (GSA) Consolidated Schedule Categories for Information Technology and Human Capital to Deloitte Consulting, LLP to support FDA’s Applicant Tracking and Lifecycle Analysis Solution (ATLAS).

a. Acquisition purpose and objectives.

The objective of this procurement is to award a BPA to provide support to the FDA ATLAS efforts in order to further automate and streamline HR processes, centralize HR tools and technology, and enable data driven decision-making regarding its workforce.

b. Project background.

In 2018, the FDA awarded a $3.2M task order (HHSN316201200018W-HHSP233201500192W) to Deloitte Consulting, LLP through an assisted acquisition with the Program Support Center (PSC) to develop a custom implementation of the licensed Deloitte ATLAS application that allows the FDA to store, track and analyze activities conducted as part of the FDA’s Shared Hiring and Stand- Alone Hiring Processes. FDA ATLAS was developed to track the lifecycle of the recruiting and hiring process at FDA with customized views for various end users, ultimately providing

Last Modified: May 18, 2016 Page 2 of 7 transparency and accountability. The FDA ATLAS tool provides the following baseline set of functionalities to support HR streamlining and automation:

• Allows the FDA to store and track activities conducted as part of the FDA’s Shared Hiring and Stand-Alone Hiring Processes.

• Allows various FDA end users (Hiring Managers, Talent Analysts, etc.) to view and interpret analytical data as part of the Hiring Pilot re-design of the hiring process.

• Provides transparency into the hiring process for end users, allowing them to track the status of vacancies within their specific purview.

• Allows users to manage tasks and conduct hiring activities within the application, providing a single point of access for certain end users throughout the application lifecycle.

• Provides personalized roles/views for vacancies and tasks that increase organization and efficiency and provide a common operating picture

• Integrates data from external hiring systems that drive an automated workflow and reduce manual activities.

• Streamlines communication between users that supports a standardized process and reduces bottlenecks and inefficiencies.

• Provides comprehensive reporting that increases transparency and provides valuable insight into the hiring process.

FDA ATLAS is currently deployed to two FDA Centers, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) with a full roll-out across FDA planned for January 2021.

3. Description of the supplies or services required to meet the agency’s needs (including the estimated value).

a. Project title.

IT Support Services for Applicant Tracking and Lifecycle Analysis Solution (ATLAS)

b. Project Description.

To support the continued aim to further enhance and deploy ATLAS beyond the pilot Centers and across FDA by January 2021 to meet User Fee Acts commitments, the Office of Operations (OO) will require a focused effort of many types of skills, services and activities to be completed across a broad spectrum of areas. The Contractor is expected to provide follow-on support through Phase Seven – Enhancements and Maintenance of the SDLC process for FDA ATLAS and associated tools which includes workflows for the less widely used hiring authorities, including but not limited to, excepted and senior executive service.

Key Tasks necessary to support the continued ATLAS effort are:

1. Applicant Tracking Lifecycle and Analytics Solution (ATLAS) Support – Conduct HR / IT Strategy, Design, Development, Modernization, Enhancements, Implementation, and Operations and Maintenance (O&M) for ATLAS and associated talent management areas.

2. Technology and Data Management – Evaluate and design the appropriate target state architecture to support organizational needs; determine and implement options to enable

Last Modified: May 18, 2016 Page 3 of 7 data integration and management between disparate processes, systems and infrastructure that increase efficiency and enable data analysis; and integrate security requirements into the architectural design in order to create or manage data needed to support ATLAS or associated processes.

Requirement type.

☒ Support services (non-R&D)

☐ Supplies/equipment

☒ Information Technology (IT)

☐ Other:

Type of action.

☐ New requirement

☒ Follow-on

☐ Other:

Proposed contract/order type.

☐ Firm-fixed-price

☐ Time and materials

☐ Indefinite delivery:

☒ Other: Blanket Purchase Agreement (BPA)

☐ Completion Form

☐ Term Form

Acquisition identification number.

OO-20-C-0067

c. Total estimated dollar value and performance/delivery period.

The estimated period of performance is August 1, 2020 – July 31, 2021 with four 12-month option years. The place of performance will be specified at the call level. The total estimated value of 5 years is $68M.

4. The authority and supporting rationale (see FAR 8.405-6(a)(1)(i); (b)(1)) and, if applicable, a demonstration of the proposed contractor’s unique qualifications to provide the required supply or service.

a. Acquisition authority.

☒ This acquisition is conducted under the authority of the Multiple Award Schedule Program. In accordance with Federal Acquisition Regulation (FAR) 8.405-6(a), consideration of schedule https://www.acquisition.gov/?q=/browse/far/8

Last Modified: May 18, 2016 Page 4 of 7 contractors will be restricted to fewer than the number required at FAR 8.405-1, FAR 8.405-2, FAR 8.405-3 (i.e., fewer than three FSS contractors). FAR 8.405-6 (a)(1)(i), for a proposed order or BPA with an estimated value exceeding the micro-purchase threshold not placed or established in accordance with the procedures in FAR 8.405-1, FAR 8.405-2, or FAR 8.405-3, the only circumstances that may justify the actions are-

☐ (A) An urgent and compelling need exists, and following the procedures would result in unacceptable delays;

☒ (B) Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized;

☐ (C) In the interest of economy and efficiency, the new work is a logical follow-on to an original Federal Supply Schedule order provided that the original order was placed in accordance with the applicable Federal Supply Schedule ordering procedures. The original order or BPA must not have been previously issued under sole-source or limited-sources procedures.

☐ This acquisition is conducted under the authority of the Multiple Award Schedule Program. In accordance with FAR 8.405-6(b), consideration of schedule contractors will be restricted only to the item peculiar to one manufacturer. An item peculiar to one manufacturer can be a particular brand name, product, or a feature of a product, peculiar to one manufacturer. A brand name item, whether available on one or more schedule contracts, is an item peculiar to one manufacturer.

b. Demonstration of the proposed contractor(s) unique qualifications to provide the required supply or service.

• Name and address of the proposed contractor(s).

DELOITTE CONSULTING LLP

1725 DUKE ST

ALEXANDRIA, VA 22314-3456

DUNS: 019121586

• Nature of the acquisition and proposed contractor(s) unique qualifications.

FDA ATLAS was developed over 18 months at a cost of $3.2M under a National Institutes of Health (NIH) Chief Information Officer Solutions and Partners 3 (CIOSP3) Government-Wide Acquisition Contract (GWAC) task order and collateral End User Licensing Agreement (EULA) between the FDA and Deloitte, dated 26 February 2018. In accordance with the EULA which grants the FDA restricted computer software rights and limited use for the ATLAS application, no modifications, upgrades, changes, or enhancements to the Licensed Solution shall be made by any third party other than Deloitte. As such, the continued enhancement and support of FDA ATLAS is deemed to be available only from the original source per FAR 8.405-6(a)(1)(i)(B).

5. Determination by the ordering activity Contracting Officer that the order represents the best value consistent with FAR 8.404(d).

https://www.acquisition.gov/?q=/browse/far/8 https://www.acquisition.gov/?q=/browse/far/8 https://www.acquisition.gov/?q=/browse/far/8 https://www.acquisition.gov/?q=/browse/far/8 https://www.acquisition.gov/?q=/browse/far/8 https://www.acquisition.gov/?q=/browse/far/8 https://www.acquisition.gov/?q=/browse/far/8

Last Modified: May 18, 2016 Page 5 of 7

GSA has already determined the prices of the supplies and services under FSS contracts, including rates for services offered at fixed hourly rates, to be fair and reasonable. Nonetheless, the CO will seek additional discounts off of GSA schedule ceiling rates. Additionally, prior to placing any orders against the BPA, the Contracting Officer will make a separate determination of fairness and reasonableness based on the specific work to be performed, associated labor categories, and level of effort.

6. Description of the market research conducted among schedule holders and the results, or a statement of the reasons market research was not conducted.

Prior to awarding a task order to Deloitte for ATLAS, the FDA evaluated several other HR Information System Solutions in different stages of development across the government in an attempt to assess their viability in meeting the FDA’s requirements and leverage investments already made by other agencies.

An analytical comparison of the operational effectiveness, suitability, risk, and life cycle cost of each solution alternative was considered and validated against capability needs. The key purpose of conducting the analysis was to identify the solution that fulfilled the requirements as optimally as possible, commensurate with established cost and schedule constraints, at the lowest practicable risk.

A final briefing of results, conclusions, and recommendations was provided to executive leadership, and the decision was made to proceed with ATLAS.

7. Any other facts supporting the justification.

None.

8. Statement of the actions, if any, the agency may take to remove or overcome any barriers that led to the restricted consideration before any subsequent acquisition for the supplies or services is made.

As analysis of alternatives is an ongoing process and a follow-on contract was contemplated. In February 2020, the Project Team conducted a critical review of ATLAS development progress relative to program milestones and metrics. The analysis included any identified deficiencies, strengths, and weaknesses regarding how well the system is meeting operational objectives and benchmarks for cost, schedule, performance and risk. These results were once again weighed against the merits of candidate solutions across other HHS OpDivs and presented to executive leadership. Proceeding with ATLAS was decided to be in the best interest of the government in terms of tradeoffs between performance, cost, schedule and risk. As FDA possesses only restricted rights to the ALTAS solution, FDA does not have the right to seek support from other contractors that may otherwise be able technically capable of providing support.

Last Modified: May 18, 2016 Page 6 of 7

9. Program office certification.

Evidence that any supporting data that is the responsibility of technical or requirements personnel (e.g., verifying the Government’s minimum needs or requirements or other rationale for limited sources) and which form a basis for the justification have been certified as complete and accurate by the technical or requirements personnel.

Signature:____________________________________

Maria Runge COR/Requiring Activity POC

Gloria Coon COR/POC Immediate Supervisor

Melanie Keller Head of the Sponsoring Program Office

10. Contracting Officer Certification.

This is to certify that the justification is accurate and complete to the best of the contracting officer’s knowledge and belief.

Sherry Solodkova Contracting Officer

Last Modified: May 18, 2016 Page 7 of 7

11. Division Director and Head of the Contracting Activity signature(s).

Andrew Jernell Division Director

Leonard D. Grant Head of the Contracting Activity

12. Competition Advocate signature.

Jim Sigg Competition Advocate